Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) rose by 6.34% to HKD 9.73, with a trading volume of HKD 1.225 billion, driven by positive forecasts regarding its business development agreements and revenue growth potential [5]. Group 1: Business Development and Revenue Projections - According to a report by Citi, CSPC's business development transactions are expected to convert into recurring revenue starting in 2026 [5]. - The agreements signed with AstraZeneca and Madrigal Pharmaceuticals are projected to bring approximately USD 10.2 billion in upfront and milestone payments, significantly boosting profits for the fiscal years 2025 to 2027 to RMB 6.3 billion, RMB 10.2 billion, and RMB 10.9 billion respectively [5]. Group 2: Sales Performance and Future Outlook - CMB International noted that CSPC has signed six business development agreements since the end of 2024, establishing a pipeline with several late-stage or differentiated drug candidates that have high potential for external licensing [5]. - The company's sales showed a slight recovery in Q3 of the previous year, with core revenue (excluding licensing income) increasing by 4.2% quarter-on-quarter, and major products also showing slight improvements [5]. - It is anticipated that drug sales will stabilize this year, with business development transactions expected to be a continuous driver of profit growth and support for dividends [5].